Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 4:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 211 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Beta adrenergic blockers Clear all
Completed Not applicable Interventional Results available

Comparative Effects of Nebivolol and Metoprolol on Female Sexual Function

NCT00995072
View directory record Official record
Conditions
Hypertension, Female Sexual Dysfunction
Interventions
nebivolol and metoprolol succinate, metoprolol succinate and nebivolol
Drug
Lead sponsor
East Coast Institute for Research
Network
Eligibility
40 Years and older · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 29, 2019 · Synced Oct 14, 2026, 4:17 PM EDT
Completed Phase 3 Interventional

Prevention of Esophageal Varices by Beta-Adrenergic Blockers

NCT00006398
View directory record Official record
Conditions
Esophageal and Gastric Varices, Liver Cirrhosis, Portal Hypertension
Interventions
Timolol Maleate, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 75 Years
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2002
U.S. locations
3
States / cities
New Haven, Connecticut • West Haven, Connecticut • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Oct 14, 2026, 4:17 PM EDT
Completed No phase listed Observational

Bicuspid Valve Aortopathy Feasibility Study

NCT01920815
View directory record Official record
Conditions
Bicuspid Aortic Valve
Interventions
No interventions
Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 90 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
6
States / cities
Los Angeles, California • Denver, Colorado • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2018 · Synced Oct 14, 2026, 4:17 PM EDT
Terminated No phase listed Observational

Assay to Measure Beta Blocker Adherence

NCT05251974
View directory record Official record
Conditions
Congestive Heart Failure, Medication Adherence
Interventions
Quest beta blocker assay
Diagnostic Test
Lead sponsor
Summa Health System
Other
Eligibility
18 Years to 89 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Akron, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 22, 2023 · Synced Oct 14, 2026, 4:17 PM EDT
Terminated Not applicable Interventional Results available

Comparing the Effects of Two Beta Blockers,Metoprolol and Nebivolol,on Ambulatory Blood Pressure and Basal Metabolic Rate

NCT00849810
View directory record Official record
Conditions
Hypertension
Interventions
Metoprolol, Nebivolol
Drug
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Mar 19, 2013 · Synced Oct 14, 2026, 4:17 PM EDT
Terminated Phase 4 Interventional Results available

Assessing the Impact of Dosage Frequency of Propranolol on Sleep Patterns in Patients With Infantile Hemangiomas

NCT05479123
View directory record Official record
Conditions
Infantile Hemangioma
Interventions
Propranolol three times a day, Propranolol twice a day, Timolol
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
Up to 18 Months
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 14, 2026, 4:17 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study on the Effect of a Beta Blocker on Increased Sensitivity to Pain in Humans Caused by Opioids

NCT01222091
View directory record Official record
Conditions
Hyperalgesia
Interventions
Propranolol, Placebo to Match Propranolol, Remifentanil
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 15, 2018 · Synced Oct 14, 2026, 4:17 PM EDT
Completed Phase 2 Interventional

Polypill Strategy for Heart Failure With Reduced Ejection Fraction

NCT04633005
View directory record Official record
Conditions
Heart Failure
Interventions
Polypill, Control Rx
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 14, 2026, 4:17 PM EDT
Completed Phase 3 Interventional Results available

Effect of Evolocumab on Coronary Atherosclerosis

NCT03689946
View directory record Official record
Conditions
Cardiovascular Disease, Hyperlipidemia
Interventions
Evolocumab, 18F-NaF PET, CCTA, Omnipaque, Metoprolol, Nitroglycerin
Drug · Diagnostic Test
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2024 · Synced Oct 14, 2026, 4:17 PM EDT
Completed Phase 2 Interventional Results available

Propranolol for Sleep Apnea Therapy

NCT03049306
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Propranolol Oral Tablet, Placebo Oral Tablet
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
20 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 5, 2024 · Synced Oct 14, 2026, 4:17 PM EDT
Completed Phase 1Phase 2 Interventional

Phase 1-2 Evaluation of OT-730 Eye Drops in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-Angle Glaucoma

NCT00753168
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
OT-730 ophthalmic solution, timolol maleate ophthalmic solution, OT-730 placebo
Drug
Lead sponsor
Othera Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
5
States / cities
Artesia, California • Roswell, Georgia • Charlotte, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2009 · Synced Oct 14, 2026, 4:17 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy of Medical Therapy in Women and Men With Angina and Myocardial Bridging

NCT04130438
View directory record Official record
Conditions
Myocardial Bridging
Interventions
Nebivolol, Diltiazem, Placebo
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2025 · Synced Oct 14, 2026, 4:17 PM EDT
Recruiting Phase 2 Interventional

Cardioprotection in AML

NCT04977180
View directory record Official record
Conditions
AML, Acute Myeloid Leukemia
Interventions
Cardioprotection
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 14, 2026, 4:17 PM EDT
Completed Phase 3 Interventional

A Study of the Safety and Efficacy of Long-Term Nebivolol Use in Hypertensive Patients

NCT00200499
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol
Drug
Lead sponsor
Mylan Bertek Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
845 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Dec 16, 2005 · Synced Oct 14, 2026, 4:17 PM EDT
Enrolling by invitation Not applicable Interventional

N-of-1 Trial to Promote Beta-Blocker Titration in Heart Failure

NCT07489352
View directory record Official record
Conditions
Heart Failure, Beta-blocker, Older Adults
Interventions
N-of-1 trials, Enhanced usual care
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
50 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 14, 2026, 4:17 PM EDT
Not listed Phase 4 Interventional

Excellence In Peripheral Artery Disease Thrombin Receptor Antagonist Intervention In Claudication Evaluation (XLPAD-TRACE Trial)

NCT02660866
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Placebo + background APT + SMT, Vorapaxar 2.08 mg/d + background APT + SMT.
Drug
Lead sponsor
North Texas Veterans Healthcare System
Federal
Eligibility
40 Years to 90 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
12
States / cities
Tucson, Arizona • San Diego, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated May 29, 2018 · Synced Oct 14, 2026, 4:17 PM EDT
Terminated Phase 4 Interventional Results available

Effectiveness of Propranolol For Treating People With Post-Traumatic Stress Disorder

NCT00648375
View directory record Official record
Conditions
Post-Traumatic Stress Disorder
Interventions
Propanolol, Placebo, Cognitive therapy workbook
Drug · Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 2, 2020 · Synced Oct 14, 2026, 4:17 PM EDT
Not listed Not applicable Interventional

Optimizing Beta Blocker Dosage in Women While Using the Wearable Cardioverter Defibrillator

NCT04504188
View directory record Official record
Conditions
Cardiomyopathies, Heart Failure
Interventions
Heart Rate Monitor Enhanced Treatment Optimization
Device
Lead sponsor
Zoll Medical Corporation
Industry
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
4
States / cities
Cincinnati, Ohio • Kingwood, Texas • McKinney, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2024 · Synced Oct 14, 2026, 4:17 PM EDT
Completed Phase 3 Interventional

Study to Evaluate the Safety of Twice Daily Oral Carvedilol

NCT00129363
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
Carvedilol
Drug
Lead sponsor
Shaddy, Robert, M.D.
Individual
Eligibility
1 Day to 17 Years
Enrollment
75 participants
Timeline
2002 – 2006
U.S. locations
17
States / cities
Los Angeles, California • Palo Alto, California • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 25, 2008 · Synced Oct 14, 2026, 4:17 PM EDT
Completed Phase 4 Interventional

Glycemic Control Of Carvedilol Versus Metoprolol In Patients With Type II Diabetes Mellitus And Hypertension

NCT00060918
View directory record Official record
Conditions
Hypertension
Interventions
carvedilol, metoprolol
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years to 80 Years
Enrollment
1,210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
50
States / cities
Glendale, Arizona • Phoenix, Arizona • Tucson, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Oct 14, 2026, 4:17 PM EDT
Withdrawn Phase 2 Interventional

Analgesic Effects of Perioperative Propranolol Administration for Spine Surgery

NCT04421209
View directory record Official record
Conditions
Lumbar Disc Disease, Spinal Fusion, Degenerative Disc Disease
Interventions
Propranolol Hcl 40mg Tab, Placebo oral tablet
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 16, 2021 · Synced Oct 14, 2026, 4:17 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Race, Natriuretic Peptides and Physiological Perturbations

NCT03070184
View directory record Official record
Conditions
Healthy, Pre Hypertension
Interventions
Exercise capacity VO2 max determination, Standardized meals, Exercise challenge, Metoprolol Succinate ER
Other · Dietary Supplement · Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 40 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2024
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Oct 14, 2026, 4:17 PM EDT
Completed Phase 4 Interventional Results available

Trial of Carvedilol in Alzheimer's Disease

NCT01354444
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Carvedilol, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
Up to 100 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 6, 2018 · Synced Oct 14, 2026, 4:17 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Exercise as an Immune Adjuvant for Allogeneic Cell Therapies

NCT06643221
View directory record Official record
Conditions
Leukemia, Hematopoetic Stem Cell Transplantation, Donor Lymphocyte Infusion, CAR T-Cell Therapy, Lymphoma, Cell Therapy
Interventions
Exercise, Isoproterenol, Placebo, Bisoprolol Fumarate Tablet 10 mg, Nadolol (1 x 80 mg) Tablets (Invamed, Inc), Carvedilol 50 mg, Roflumilast 500 Mcg Oral Tablet
Behavioral · Drug
Lead sponsor
University of Arizona
Other
Eligibility
21 Years to 55 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2031
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 14, 2026, 4:17 PM EDT